We are live on ! Find out more
BB Biotech

BB Biotech Portfolio holdings

AUM $3.98B Turnover 8.33%
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+4.2%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.62B
AUM Growth
+$67.2M
Cap. Flow
+$35.4M
Cap. Flow %
0.98%
Top 10 Hldgs %
68.09%
Holding
31
New
1
Increased
12
Reduced
6
Closed
1
Avg Time Held
3 years
Top 10 Avg Time Held
3.1 years
Top 20 Avg Time Held
3.2 years

Top Buys

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$37.5M
2
ARGX icon
argenx
ARGX
+$30M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$26.1M
4
AKCA
Akcea Therapeutics Inc
AKCA
+$24.6M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$19.3M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$88M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$14.3M
3
CELG
Celgene Corp
CELG
+$9.6M
4
GILD icon
Gilead Sciences
GILD
+$7.95M
5
SAGE icon
Sage Therapeutics
SAGE
+$6.79M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IONS icon
1
Ionis Pharmaceuticals
IONS
$4.84B
$375M 10.37%
8,516,334
+380,000
+5% +$19.3M
2013 Q2
19 quarters
INCY icon
2
Incyte
INCY
$24.7B
$308M 8.52%
3,698,322
– –
2013 Q2
19 quarters
CELG
3
DELISTED
Celgene Corp
CELG
$297M 8.2%
3,324,298
-100,000
-3% -$9.6M
2013 Q2
19 quarters
NBIX icon
4
Neurocrine Biosciences
NBIX
$16.9B
$282M 7.8%
3,402,753
-50,000
-1% -$4.22M
2013 Q3
18 quarters
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$137B
$240M 6.65%
1,475,445
– –
2013 Q2
19 quarters
RDUS icon
6
DELISTED
Radius Health, Inc.
RDUS
$210M 5.81%
5,853,799
+155,000
+3% +$5.6M
2014 Q2
15 quarters
AGIO icon
7
Agios Pharmaceuticals
AGIO
$1.89B
$207M 5.73%
2,535,253
-184,745
-7% -$14.3M
2014 Q2
15 quarters
GILD icon
8
Gilead Sciences
GILD
$208B
$202M 5.57%
2,674,596
-100,000
-4% -$7.95M
2013 Q2
19 quarters
ESPR icon
9
DELISTED
Esperion Therapeutics
ESPR
$175M 4.82%
2,412,964
+50,000
+2% +$3.67M
2015 Q3
10 quarters
HALO icon
10
Halozyme
HALO
$11.4B
$167M 4.61%
8,520,137
– –
2013 Q2
19 quarters
SAGE icon
11
DELISTED
Sage Therapeutics
SAGE
$161M 4.46%
1,002,439
-40,000
-4% -$6.79M
2015 Q4
9 quarters
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
$155M 4.3%
1,394,428
+40,000
+3% +$4.78M
2013 Q2
19 quarters
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$22.1B
$120M 3.33%
1,011,338
-40,000
-4% -$5.16M
2013 Q2
19 quarters
REGN icon
14
Regeneron Pharmaceuticals
REGN
$98.8B
$96.4M 2.66%
280,000
+75,000
+37% +$26.1M
2013 Q3
18 quarters
TSRO
15
DELISTED
TESARO, Inc.
TSRO
$93.1M 2.57%
1,629,743
+583,550
+56% +$37.5M
2013 Q3
18 quarters
MYOV
16
DELISTED
Myovant Sciences Ltd.
MYOV
$74.6M 2.06%
3,507,882
– –
2016 Q4
5 quarters
MGNX icon
17
MacroGenics
MGNX
$140M
$65.4M 1.81%
2,600,412
– –
2016 Q2
7 quarters
AKCA
18
DELISTED
Akcea Therapeutics Inc
AKCA
$61.2M 1.69%
2,389,571
+1,140,921
+91% +$24.6M
2017 Q4
1 quarter
AVXS
19
DELISTED
AveXis, Inc. Common Stock
AVXS
$49.8M 1.38%
402,800
– –
2016 Q3
6 quarters
ITCI icon
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$46.3M 1.28%
2,200,000
– –
2016 Q2
7 quarters
VYGR icon
21
Voyager Therapeutics
VYGR
$108M
$37.4M 1.03%
1,992,641
+453,121
+29% +$9.8M
2017 Q4
1 quarter
WVE icon
22
Wave Life Sciences
WVE
$617M
$35.9M 0.99%
896,096
+40,000
+5% +$1.68M
2017 Q4
1 quarter
ICPT
23
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$33.6M 0.93%
545,719
+60,000
+12% +$3.62M
2015 Q1
12 quarters
ARGX icon
24
argenx
ARGX
$60.4B
$31.9M 0.88%
+396,819
New +$30M
2018 Q1
0 quarters
ALDR
25
DELISTED
Alder Biopharmaceuticals
ALDR
$28.8M 0.8%
2,266,008
– –
2015 Q2
11 quarters
1
2

Similar funds

Santa Barbara Asset Management
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HL Financial Services
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WealthTrust Fairport
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
Bain Capital Public Equity Management
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Daruma Capital Management
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AT Bancorp
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MB Financial Bank - Trust Department
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q1 2018 Portfolio in Review

As of Q1 2018, BB Biotech held 31 positions worth $3.62B, up 1.9% from $3.55B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

BB Biotech's Q1 2018 filing shows 1 new, 12 increased, 6 reduced and 1 closed positions. Its largest new stake was argenx: 396,819 shares worth $31.9M. The largest sale was Juno Therapeutics, Inc., an estimated $88M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • BB Biotech's largest Q1 2018 buy was argenx: 396,819 shares worth $31.9M.
  • BB Biotech added most to TESARO, Inc. in Q1 2018, an estimated $37.5M increase.
  • BB Biotech's biggest Q1 2018 reduction was Agios Pharmaceuticals, cutting an estimated $14.3M.
  • BB Biotech fully exited Juno Therapeutics, Inc. in Q1 2018, selling an estimated $88M.
  • BB Biotech's ten largest holdings make up 68% of its $3.62B portfolio in Q1 2018.
  • BB Biotech opened 1 new position and closed 1 in Q1 2018.
  • BB Biotech's portfolio value rose 1.9% quarter-over-quarter to $3.62B.

Based on BB Biotech's 13F filing for Q1 2018, filed 8 May 2018.